The present invention refers to specifically deuterated palbociclib derivatives, wherein carbon atoms of the piperazine ring are deuterated. Like palbociclib these deuterated derivatives are cyclin-dependent kinase 4 (CDK-4) inhibitors for treating cancer. These specifically deuterated derivatives have an improved metabolic stability.